[RummyChick]

I think the patent ran out before the trials would be over. 2015. 4 years. Patent ran out in 2018.

[Bruce Campbells Chin]

Right -- but Pfizer would have had a jump on developing a modified, patentable version of the drug specifically targeted at Alzheimers, and could perhaps have gotten a brand new patent for it.

By doing nothing, they lost whatever advantage they would have had in trying to develop a version of the drug specifically targeted at Alzheimers.

That leads me to believe that Pfizer was telling the truth about why they didn't pursue it.